217 related articles for article (PubMed ID: 21463127)
81. Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma.
Li Z; Lu L; Zhou Z; Xue W; Wang Y; Jin M; Qiu Y; Sun W; Fu X; Zhang X; Chang Y; Nan F; Yan J; Wang G; Sun Z; Fu X; Li L; Li X; Wang X; Wu J; Zhang L; Zhang M
Br J Haematol; 2018 May; 181(3):406-410. PubMed ID: 28294301
[No Abstract] [Full Text] [Related]
82. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia.
Bonnet M; Loosveld M; Montpellier B; Navarro JM; Quilichini B; Picard C; Di Cristofaro J; Bagnis C; Fossat C; Hernandez L; Mamessier E; Roulland S; Morgado E; Formisano-Tréziny C; Dik WA; Langerak AW; Prebet T; Vey N; Michel G; Gabert J; Soulier J; Macintyre EA; Asnafi V; Payet-Bornet D; Nadel B
Blood; 2011 Jun; 117(24):6650-9. PubMed ID: 21527520
[TBL] [Abstract][Full Text] [Related]
83. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.
Shojaee S; Chan LN; Buchner M; Cazzaniga V; Cosgun KN; Geng H; Qiu YH; von Minden MD; Ernst T; Hochhaus A; Cazzaniga G; Melnick A; Kornblau SM; Graeber TG; Wu H; Jumaa H; Müschen M
Nat Med; 2016 Apr; 22(4):379-87. PubMed ID: 26974310
[TBL] [Abstract][Full Text] [Related]
84. Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia.
Gao J; Van Meter M; Hernandez Lopez S; Chen G; Huang Y; Ren S; Zhao Q; Rojas J; Gurer C; Thurston G; Kuhnert F
Dis Model Mech; 2019 Sep; 12(9):. PubMed ID: 31399482
[TBL] [Abstract][Full Text] [Related]
85. Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia.
Lee K; Nam KT; Cho SH; Gudapati P; Hwang Y; Park DS; Potter R; Chen J; Volanakis E; Boothby M
J Exp Med; 2012 Apr; 209(4):713-28. PubMed ID: 22473959
[TBL] [Abstract][Full Text] [Related]
86. Miltefosine suppression of Pten null T-ALL leukemia via β-catenin degradation through inhibition of pT308-Akt and TGFβ1/Smad3.
Zhang Y; Lee S; Xu W
Biochem Biophys Res Commun; 2020 Apr; 524(4):1018-1024. PubMed ID: 32063363
[TBL] [Abstract][Full Text] [Related]
87. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia.
Gutierrez A; Grebliunaite R; Feng H; Kozakewich E; Zhu S; Guo F; Payne E; Mansour M; Dahlberg SE; Neuberg DS; den Hertog J; Prochownik EV; Testa JR; Harris M; Kanki JP; Look AT
J Exp Med; 2011 Aug; 208(8):1595-603. PubMed ID: 21727187
[TBL] [Abstract][Full Text] [Related]
88. Targeting NOTCH1 in T-ALL: Starving the dragon.
Herranz D; Ferrando AA
Cell Cycle; 2016; 15(4):483-4. PubMed ID: 26864725
[No Abstract] [Full Text] [Related]
89. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.
Chan SM; Weng AP; Tibshirani R; Aster JC; Utz PJ
Blood; 2007 Jul; 110(1):278-86. PubMed ID: 17363738
[TBL] [Abstract][Full Text] [Related]
90. TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia.
Thielemans N; Demeyer S; Mentens N; Gielen O; Provost S; Cools J
Haematologica; 2022 Oct; 107(10):2304-2317. PubMed ID: 35354248
[TBL] [Abstract][Full Text] [Related]
91. Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis.
Zhang C; Ryu YK; Chen TZ; Hall CP; Webster DR; Kang MH
Leuk Res; 2012 Mar; 36(3):342-9. PubMed ID: 22137317
[TBL] [Abstract][Full Text] [Related]
92. The PTEN⁻PI3K Axis in Cancer.
Papa A; Pandolfi PP
Biomolecules; 2019 Apr; 9(4):. PubMed ID: 30999672
[TBL] [Abstract][Full Text] [Related]
93. Leukemia propagating cells Akt up.
Gutierrez A; Roderick JE; Kelliher MA
Cancer Cell; 2014 Mar; 25(3):263-5. PubMed ID: 24651006
[TBL] [Abstract][Full Text] [Related]
94. Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia.
Lim FQ; Chan AS; Yokomori R; Huang XZ; Theardy MS; Yeoh AEJ; Tan SH; Sanda T
Haematologica; 2023 Feb; 108(2):367-381. PubMed ID: 36073513
[TBL] [Abstract][Full Text] [Related]
95. Resistance mechanism to Notch inhibition and combination therapy in human T-cell acute lymphoblastic leukemia.
Cao L; Ruiz Buendía GA; Fournier N; Liu Y; Armand F; Hamelin R; Pavlou M; Radtke F
Blood Adv; 2023 Oct; 7(20):6240-6252. PubMed ID: 37358480
[TBL] [Abstract][Full Text] [Related]
96. mTOR deregulation in oral cavity squamous cell carcinoma.
Mastronikolis NS; Tsiambas E; Papadas TA; Fotiades PP; Papadas AT; Mastronikolis SN; Kastanioudakis I; Ragos V
J BUON; 2017; 22(3):610-613. PubMed ID: 28730764
[TBL] [Abstract][Full Text] [Related]
97. β-Catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL.
Kaveri D; Kastner P; Dembélé D; Nerlov C; Chan S; Kirstetter P
Blood; 2013 Aug; 122(5):694-704. PubMed ID: 23801632
[TBL] [Abstract][Full Text] [Related]
98. Neuronal deletion of phosphatase and tensin homolog results in cerebellar motor learning dysfunction and alterations in intracellular signaling.
Nolan SO; Jefferson TS; Reynolds CD; Smith GD; Holley AJ; Hodges SL; Lugo JN
Neuroreport; 2019 May; 30(8):556-561. PubMed ID: 30920436
[TBL] [Abstract][Full Text] [Related]
99. Modulating the strength and threshold of NOTCH oncogenic signals by mir-181a-1/b-1.
Fragoso R; Mao T; Wang S; Schaffert S; Gong X; Yue S; Luong R; Min H; Yashiro-Ohtani Y; Davis M; Pear W; Chen CZ
PLoS Genet; 2012; 8(8):e1002855. PubMed ID: 22916024
[TBL] [Abstract][Full Text] [Related]
100. [Reaserch Advances on the Role of PI3K/AKT Signaling Pathway and MiRNA in Acute T-Cell Lymphocytic Leukemia--Review].
Li YJ; Li XF; Yang EH; Shi M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1344-1347. PubMed ID: 31418405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
